Our Pipeline
We are programming biology to create optimal therapeutics for the greatest impact on human health.
| Program | Target | Indication | Generating | IND-enabling | Phase 1 | Collaborations | ||
|---|---|---|---|---|---|---|---|---|
| Immunology | ||||||||
| GB-0895 | TSLP | Severe Asthma |
Phase Phase 1 |
|||||
| GB-0895 | TSLP | COPD |
Phase Phase 1 |
|||||
| GB-7624 | IL-13 | Atopic Dermatitis |
Phase Phase 1 |
|||||
| Coform and bispecific | TSLP x IL-13 | Severe Asthma |
Phase IND-enabling |
|||||
| mAb | TL1A | Ulcerative Colitis |
Phase Generating |
|||||
| mAb | OX40L | Atopic Dermatitis |
Phase Generating |
|||||
| Bispecific | TL1A x IL-23 | Ulcerative Colitis |
Phase Generating |
|||||
| Mono and combo incl. bsAb |
Various |
Phase Generating |
||||||
| Immuno-oncology | ||||||||
| Armored CAR-T | Undisclosed | Advanced Solid Tumors |
Phase IND-enabling |
Collaborations 
50/50
|
||||
| Bispecific | Undisclosed | NSCLC |
Phase Generating |
Collaborations
The University of Texas
MD Anderson Cancer Center 50/50 |
||||
| ADCs | ||||||||
| Protein Binder | Free MMAE | ADC Toxin Neutralizer |
Phase IND-enabling |
|||||
| ADC | Undisclosed | Advanced Solid Tumors |
Phase Generating |
|||||
| Infectious Disease | ||||||||
| GB-0669* | SARS-CoV-2 S2 | Covid-19 |
Phase Phase 1 |
|||||
| mAb* | SARS-CoV-2 RBD cl.IV | Covid-19 |
Phase IND-enabling |
|||||
| Undisclosed | ||||||||
| Amgen |
6 Undisclosed Programs
|
Collaborations 
|
||||||
| Novartis |
Multiple Undisclosed Programs
|
Collaborations 
|
||||||
|
*Deprioritized for internal development |
||||||||
Policy on Expanded Access (EA) to Investigational Drugs
Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.